RHEB (GTP-binding protein Rheb) variants and mutations
RHEB (also known as GTP-binding protein Rheb) is a human protein-coding gene encoding a GTP-binding protein. Its GTP-bound form directly activates mTORC1 in response to growth and nutrient signals and is normally restrained by the TSC1-TSC2 complex. Activating variants can cause neurodevelopmental overgrowth and epilepsy phenotypes through excessive mTOR signaling. This analysis covers 293 RHEB variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes isolated focal cortical dysplasia type II, neurodegenerative disease, and coronary artery disorder. Example RHEB variants include S4Y, S6A, and I11M.
Variant analysis overview
- Gene: RHEB
- Protein: GTP-binding protein Rheb
- UniProt accession: Q15382
- Organism: Homo sapiens
- Variants analyzed: 293
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 123 unspecified-consequence records; 1 stop retained variant; 1 stop lost; 57 synonymous variants; 6 stop-gained variants; 89 missense variants; 6 splice-region variants; 8 frameshift variants; 2 substitution
- Prediction scores: 225 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: isolated focal cortical dysplasia type II, neurodegenerative disease, coronary artery disorder, hemimegalencephaly, response to xenobiotic stimulus, Intellectual disability, deficiency anemia, poisoning, coronary atherosclerosis, gout, hypertensive disorder, chronic kidney disease.
Protein structure and variant hotspots
- Protein features: 24 binding sites; 2 post-translational modification sites.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable RHEB variants
Examples include S4Y, S6A, I11M, G13D, G13S, Y14C, R15P, R15Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- S4Y (p.Ser4Tyr), ExAC rs760928726, gnomAD rs760928726, REVEL 0.17, MetaLR 0.35
- S6A (p.Ser6Ala), ExAC rs773531665, gnomAD rs773531665, REVEL 0.27, MetaLR 0.28
- I11M (p.Ile11Met), 1000Genomes rs532923868, ExAC rs532923868, TOPMed rs532923868, gnomAD rs532923868, REVEL 0.39, MetaLR 0.39
- G13D (p.Gly13Asp), NCI-TCGA Cosmic COSV1000, REVEL 0.90, MetaLR 0.98, Variant assessed as somatic; moderate impact.
- G13S (p.Gly13Ser), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- Y14C (p.Tyr14Cys), gnomAD rs1360165609, REVEL 0.55, MetaLR 0.49
- R15P (p.Arg15Pro), ExAC rs769657232, TOPMed rs769657232, gnomAD rs769657232, REVEL 0.60, MetaLR 0.36
- R15Q (p.Arg15Gln), ExAC rs769657232, TOPMed rs769657232, gnomAD rs769657232, REVEL 0.60, MetaLR 0.38
- S16F (p.Ser16Phe), rs1803142082, ClinGen CA370068357, ClinVar RCV001725806, Ensembl rs1803142082, REVEL 0.62, MetaLR 0.47, Uncertain significance, Seizure; Neurodevelopmental delay
- T23M (p.Thr23Met), rs867628277, NCI-TCGA Cosmic COSV5126, Ensembl rs867628277, REVEL 0.72, MetaLR 0.35, Uncertain significance, not specified
- I24F (p.Ile24Phe), Ensembl rs1802570951
- I24T (p.Ile24Thr), rs2536111808, ClinGen CA370052716, ClinVar RCV003570739, ClinVar RCV005410964, Conflicting interpretations, not provided; Intellectual disability
- I24V (p.Ile24Val), NCI-TCGA Cosmic COSV5126, REVEL 0.47, MetaLR 0.32, Variant assessed as somatic; moderate impact.
- Q25R (p.Gln25Arg), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- F26C (p.Phe26Cys), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- F26L (p.Phe26Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G29S (p.Gly29Ser), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- Y35C (p.Tyr35Cys), rs1057519950, ClinGen CA16602945, NCI-TCGA Cosmic COSV5126, AlphaMissense 0.95, MetaLR 0.64, Pathogenic, not provided
- Y35F (p.Tyr35Phe), gnomAD rs1057519950, Pathogenic
- Y35H (p.Tyr35His), Ensembl rs1057519949
- Y35L (p.Tyr35Leu), rs2536111758, ClinVar RCV004566491, Pathogenic, Isolated focal cortical dysplasia type IIb; Isolated focal cortical dysplasia ty
- Y35N (p.Tyr35Asn), rs1057519949, NCI-TCGA Cosmic COSV5126, Ensembl rs1057519949, AlphaMissense 0.98, MetaLR 0.74, Likely pathogenic
- Y35S (p.Tyr35Ser), rs1057519950, ClinGen CA370052638, ClinVar RCV002278969, gnomAD rs1057519950, AlphaMissense 0.95, MetaLR 0.64, Pathogenic, not provided
- D36N (p.Asp36Asn), gnomAD rs1454894396, REVEL 0.50, MetaLR 0.56
- I39T (p.Ile39Thr), TOPMed rs1802570192
- E40V (p.Glu40Val), rs1554438588, ClinGen CA370052603, NCI-TCGA Cosmic COSV5126, ClinVar RCV000656704, AlphaMissense 0.99, MetaLR 0.69, Likely pathogenic, Hemimegalencephaly
- T42I (p.Thr42Ile), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- T42N (p.Thr42Asn), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- I47M (p.Ile47Met), TOPMed rs1802438993, gnomAD rs1802438993, REVEL 0.43, MetaLR 0.34
- I47S (p.Ile47Ser), Ensembl rs1802439076
- V49E (p.Val49Glu), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- V49I (p.Val49Ile), Ensembl rs1802438807
- N50S (p.Asn50Ser), TOPMed rs1278044521, gnomAD rs1278044521, REVEL 0.33, MetaLR 0.39
- N50Y (p.Asn50Tyr), 1000Genomes rs565872320, ExAC rs565872320, gnomAD rs565872320, REVEL 0.80, MetaLR 0.60
- G51R (p.Gly51Arg), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- E53D (p.Glu53Asp), gnomAD rs1345529849, NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- Q57* (p.Gln57Ter), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; high impact.
- L58P (p.Leu58Pro), 1000Genomes rs201447147
- L58R (p.Leu58Arg), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- V59I (p.Val59Ile), Ensembl rs1802437970
- D60V (p.Asp60Val), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- G63R (p.Gly63Arg), Ensembl rs1802437887, REVEL 0.94, MetaLR 0.93, Uncertain significance, not provided
- G63W (p.Gly63Trp), NCI-TCGA Cosmic COSV5126, Variant assessed as somatic; moderate impact.
- D65=, NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; low impact.
- D65H (p.Asp65His), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- D65G (p.Asp65Gly), gnomAD 7-151477414-T-C, REVEL 0.91, MetaLR 0.63
- D65Y (p.Asp65Tyr), gnomAD 7-151477415-C-A, REVEL 0.86, MetaLR 0.64
- E66E (p.Glu66Glu), rs1802290092, gnomAD 7-151477410-T-C, CADD 13.10
- E66G (p.Glu66Gly), gnomAD 7-151477411-T-C, REVEL 0.91, MetaLR 0.67
- Y67F (p.Tyr67Phe), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- Y67Y (p.Tyr67Tyr), gnomAD 7-151477407-A-G, CADD 8.81
- S68S (p.Ser68Ser), gnomAD 7-151477404-A-G, CADD 11.70
- S68Y (p.Ser68Tyr), gnomAD 7-151477405-G-T, REVEL 0.84, MetaLR 0.64
- S68P (p.Ser68Pro), gnomAD 7-151477406-A-G, REVEL 0.83, MetaLR 0.55
- I69L (p.Ile69Leu), TOPMed rs1294581220, gnomAD rs1294581220, REVEL 0.36, MetaLR 0.17
- I69V (p.Ile69Val), TOPMed rs1294581220, gnomAD rs1294581220, REVEL 0.26, MetaLR 0.22
- I69I (p.Ile69Ile), gnomAD 7-151477401-G-T, CADD 10.60
- I69T (p.Ile69Thr), gnomAD 7-151477402-A-G, REVEL 0.68, MetaLR 0.30
- F70F (p.Phe70Phe), gnomAD 7-151477398-A-G, CADD 11.20
- F70S (p.Phe70Ser), gnomAD 7-151477399-A-G, REVEL 0.87, MetaLR 0.56
- F70L (p.Phe70Leu), gnomAD 7-151477400-A-G, REVEL 0.44, MetaLR 0.10
- P71P (p.Pro71Pro), gnomAD 7-151477395-A-G, CADD 13.30
- P71T (p.Pro71Thr), gnomAD 7-151477397-G-T, REVEL 0.71, MetaLR 0.41
- P71S (p.Pro71Ser), gnomAD 7-151477397-G-A, REVEL 0.64, MetaLR 0.49
- Q72H (p.Gln72His), TOPMed rs1397979808, gnomAD rs1397979808, REVEL 0.54, MetaLR 0.43
- Q72R (p.Gln72Arg), gnomAD 7-151477393-T-C, REVEL 0.48, MetaLR 0.20
- Q72* (p.Gln72Ter), gnomAD 7-151477394-G-A, CADD 45.00
- Q72K (p.Gln72Lys), gnomAD 7-151477394-G-T, REVEL 0.40, MetaLR 0.22
- T73T (p.Thr73Thr), rs969145070, gnomAD 7-151477389-T-C, CADD 8.90
- T73I (p.Thr73Ile), gnomAD 7-151477390-G-A, REVEL 0.62, MetaLR 0.31
- T73K (p.Thr73Lys), gnomAD 7-151477390-G-T, REVEL 0.46, MetaLR 0.20
- Y74* (p.Tyr74Ter), gnomAD 7-151477386-G-T, CADD 42.00
- Y74Y (p.Tyr74Tyr), gnomAD 7-151477386-G-A, CADD 10.30
- Y74C (p.Tyr74Cys), gnomAD 7-151477387-T-C, REVEL 0.95, MetaLR 0.63
- S75C (p.Ser75Cys), ExAC rs771041474, gnomAD rs771041474, REVEL 0.65, MetaLR 0.31
- S75S (p.Ser75Ser), gnomAD 7-151477383-G-T, CADD 12.80
- S75Y (p.Ser75Tyr), gnomAD 7-151477384-G-T, REVEL 0.61, MetaLR 0.26
- S75P (p.Ser75Pro), gnomAD 7-151477385-A-G, REVEL 0.78, MetaLR 0.58
- I76M (p.Ile76Met), gnomAD 7-151477380-T-C, REVEL 0.25, MetaLR 0.39
- I76I (p.Ile76Ile), gnomAD 7-151477380-T-G, CADD 12.40
- I76T (p.Ile76Thr), gnomAD 7-151477381-A-G, REVEL 0.51, MetaLR 0.33
- I76V (p.Ile76Val), gnomAD 7-151477382-T-C, REVEL 0.21, MetaLR 0.34
- D77D (p.Asp77Asp), rs747151926, gnomAD 7-151477377-A-G, CADD 10.60
- I78T (p.Ile78Thr), TOPMed rs1475336718
- I78V (p.Ile78Val), TOPMed rs1802289477, gnomAD rs1802289477, REVEL 0.33, MetaLR 0.20
- I78I (p.Ile78Ile), gnomAD 7-151477374-A-G, CADD 11.80
- N79S (p.Asn79Ser), TOPMed rs1189535209
- N79M (p.Asn79Met), gnomAD 7-151477371-AT-A, CADD 32.00
- G80G (p.Gly80Gly), gnomAD 7-151477368-G-C, CADD 8.88
- G80D (p.Gly80Asp), gnomAD 7-151477369-C-T, REVEL 0.97, MetaLR 0.84
- Y81Y (p.Tyr81Tyr), gnomAD 7-151477365-A-G, CADD 6.85
- Y81H (p.Tyr81His), gnomAD 7-151477367-A-G, REVEL 0.92, MetaLR 0.70
- I82T (p.Ile82Thr), gnomAD 7-151477363-A-G, REVEL 0.93, MetaLR 0.77
- L83L (p.Leu83Leu), rs1802289222, gnomAD 7-151477359-A-G, CADD 9.19
- L83P (p.Leu83Pro), gnomAD 7-151477360-A-G, REVEL 0.94, MetaLR 0.82
- L83I (p.Leu83Ile), gnomAD 7-151477361-G-T, REVEL 0.61, MetaLR 0.54
- V84A (p.Val84Ala), Ensembl rs776865999, REVEL 0.88, MetaLR 0.81
- V84V (p.Val84Val), gnomAD 7-151477356-C-T, CADD 11.50
- V84M (p.Val84Met), gnomAD 7-151477358-C-T, REVEL 0.88, MetaLR 0.82
- Y85C (p.Tyr85Cys), gnomAD rs1327307104
- S86Y (p.Ser86Tyr), gnomAD 7-151477351-G-T, REVEL 0.93, MetaLR 0.79
- V87I (p.Val87Ile), gnomAD 7-151477349-C-T, REVEL 0.27, MetaLR 0.17
- T88A (p.Thr88Ala), ExAC rs777846252, gnomAD rs777846252, REVEL 0.80, MetaLR 0.40
- T88T (p.Thr88Thr), gnomAD 7-151477344-T-G, CADD 12.40
- T88K (p.Thr88Lys), gnomAD 7-151477345-G-T, REVEL 0.87, MetaLR 0.73
- S89* (p.Ser89Ter), gnomAD 7-151477342-G-T, CADD 49.00
- S89P (p.Ser89Pro), gnomAD 7-151477343-A-G, REVEL 0.88, MetaLR 0.72
- I90M (p.Ile90Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I90V (p.Ile90Val), TOPMed rs1401324113, gnomAD rs1401324113, REVEL 0.20, MetaLR 0.22
- I90I (p.Ile90Ile), gnomAD 7-151477338-G-T, CADD 10.90
- I90T (p.Ile90Thr), gnomAD 7-151477339-A-G, REVEL 0.20, MetaLR 0.18
- I90L (p.Ile90Leu), gnomAD 7-151477340-T-G, REVEL 0.27, MetaLR 0.14
- K91N (p.Lys91Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S92S (p.Ser92Ser), gnomAD 7-151471605-A-G, CADD 12.00, SIFT 0.00
- S92V (p.Ser92Val), gnomAD 7-151477333-CT-C, CADD 32.00
- S92G (p.Ser92Gly), gnomAD 7-151477334-T-C, REVEL 0.95, MetaLR 0.83
- F93F (p.Phe93Phe), rs1802162279, gnomAD 7-151471602-A-G, CADD 13.30
- E94E (p.Glu94Glu), gnomAD 7-151471599-T-C, CADD 13.10
- E94G (p.Glu94Gly), gnomAD 7-151471600-T-C, REVEL 0.83, MetaLR 0.62
- K97K (p.Lys97Lys), rs747520707, gnomAD 7-151471590-T-C, CADD 13.10
- K97R (p.Lys97Arg), gnomAD 7-151471591-T-C, REVEL 0.18, MetaLR 0.25
- K97E (p.Lys97Glu), gnomAD 7-151471592-T-C, REVEL 0.29, MetaLR 0.26
- I99I (p.Ile99Ile), rs1156810807, gnomAD 7-151471584-G-A, CADD 13.10
- H100R (p.His100Arg), ExAC rs772187036, gnomAD rs772187036, REVEL 0.58, MetaLR 0.24
- H100Y (p.His100Tyr), ESP rs375061279, ExAC rs375061279, TOPMed rs375061279, gnomAD rs375061279, REVEL 0.39, MetaLR 0.19
- H100H (p.His100His), rs200487961, gnomAD 7-151471581-A-G, CADD 7.86
- H100N (p.His100Asn), gnomAD 7-151471583-G-T, REVEL 0.62, MetaLR 0.51
- G101G (p.Gly101Gly), gnomAD 7-151471578-G-T, CADD 9.84
- G101D (p.Gly101Asp), gnomAD 7-151471579-C-T, REVEL 0.30, MetaLR 0.09
- G101S (p.Gly101Ser), gnomAD 7-151471580-C-T, REVEL 0.28, MetaLR 0.16
- K102I (p.Lys102Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L103V (p.Leu103Val), gnomAD 7-151471574-A-C, REVEL 0.59, MetaLR 0.39
- D105D (p.Asp105Asp), rs1452220145, gnomAD 7-151471566-A-G, CADD 4.77
- D105N (p.Asp105Asn), gnomAD 7-151471568-C-T, REVEL 0.44, MetaLR 0.47
- M106I (p.Met106Ile), gnomAD rs1248045931
- V107V (p.Val107Val), rs1239392247, gnomAD 7-151471560-C-T, CADD 14.20
- K109E (p.Lys109Glu), gnomAD rs78413506
- V110Y (p.Val110Tyr), gnomAD 7-151471553-CT-C, CADD 32.00
- Q111H (p.Gln111His), ESP rs374943192, ExAC rs374943192, TOPMed rs374943192, gnomAD rs374943192, REVEL 0.24, MetaLR 0.20
- Q111Q (p.Gln111Gln), gnomAD 7-151471441-T-C, CADD 10.40
- Q111* (p.Gln111Ter), gnomAD 7-151471550-G-A, CADD 45.00
- Q111K (p.Gln111Lys), gnomAD 7-151471550-G-T, REVEL 0.26, MetaLR 0.20
- I112M (p.Ile112Met), gnomAD 7-151471438-T-C, REVEL 0.42, MetaLR 0.31
- I112K (p.Ile112Lys), gnomAD 7-151471439-A-T, REVEL 0.86, MetaLR 0.49
- I112T (p.Ile112Thr), gnomAD 7-151471439-A-G, REVEL 0.69, MetaLR 0.39
- I112L (p.Ile112Leu), gnomAD 7-151471440-T-A, REVEL 0.29, MetaLR 0.26
- I112V (p.Ile112Val), gnomAD 7-151471440-T-C, REVEL 0.20, MetaLR 0.16
- P113H (p.Pro113His), gnomAD 7-151471436-G-T, REVEL 0.90, MetaLR 0.81
- P113T (p.Pro113Thr), gnomAD 7-151471437-G-T, REVEL 0.91, MetaLR 0.73
- I114V (p.Ile114Val), TOPMed rs1802159781, REVEL 0.22, MetaLR 0.31
- I114I (p.Ile114Ile), rs202221940, gnomAD 7-151471432-A-G, CADD 12.60
- M115I (p.Met115Ile), Ensembl rs1802159654, REVEL 0.28, MetaLR 0.17, Uncertain significance, not provided
- M115R (p.Met115Arg), gnomAD 7-151471430-A-C, REVEL 0.90, MetaLR 0.51
- M115C (p.Met115Cys), gnomAD 7-151471431-TA-T, CADD 28.50
- L116S (p.Leu116Ser), 1000Genomes rs556268622, REVEL 0.97, MetaLR 0.83
- L116L (p.Leu116Leu), gnomAD 7-151471426-C-T, CADD 15.40
- L116F (p.Leu116Phe), gnomAD 7-151471426-C-A, REVEL 0.78, MetaLR 0.79
- V117V (p.Val117Val), gnomAD 7-151471423-A-G, CADD 9.70
- V117A (p.Val117Ala), gnomAD 7-151471424-A-G, REVEL 0.93, MetaLR 0.75
- V117I (p.Val117Ile), gnomAD 7-151471425-C-T, REVEL 0.73, MetaLR 0.70
- G118G (p.Gly118Gly), gnomAD 7-151471420-C-T, CADD 8.44
- G118E (p.Gly118Glu), gnomAD 7-151471421-C-T, REVEL 0.97, MetaLR 0.87
- G118R (p.Gly118Arg), gnomAD 7-151471422-C-T, REVEL 0.96, MetaLR 0.86
- G118W (p.Gly118Trp), gnomAD 7-151471422-C-A, REVEL 0.93, MetaLR 0.87
- N119N (p.Asn119Asn), gnomAD 7-151471417-A-G, CADD 12.40
- N119K (p.Asn119Lys), gnomAD 7-151471417-A-T, REVEL 0.82, MetaLR 0.87
- N119S (p.Asn119Ser), gnomAD 7-151471418-T-C, REVEL 0.89, MetaLR 0.80
- N119I (p.Asn119Ile), gnomAD 7-151471419-TC-T, CADD 23.70
- N119D (p.Asn119Asp), gnomAD 7-151471419-T-C, REVEL 0.89, MetaLR 0.89
- K120K (p.Lys120Lys), gnomAD 7-151471414-C-T, CADD 12.00
- K120R (p.Lys120Arg), gnomAD 7-151471415-T-C, REVEL 0.95, MetaLR 0.94
- K120* (p.Lys120Ter), gnomAD 7-151471416-T-A, CADD 42.00
- K120E (p.Lys120Glu), gnomAD 7-151471416-T-C, REVEL 0.97, MetaLR 0.95
- K121E (p.Lys121Glu), TOPMed rs962426677, REVEL 0.46, MetaLR 0.38
- K121N (p.Lys121Asn), gnomAD 7-151471411-T-A, REVEL 0.22, MetaLR 0.20
- K121K (p.Lys121Lys), rs371875899, gnomAD 7-151471411-T-C, CADD 10.50
- K121R (p.Lys121Arg), gnomAD 7-151471412-T-C, REVEL 0.26, MetaLR 0.32
- D122E (p.Asp122Glu), gnomAD 7-151471408-G-T, REVEL 0.92, MetaLR 0.94
- D122G (p.Asp122Gly), gnomAD 7-151471409-T-C, REVEL 0.99, MetaLR 0.96
- L123L (p.Leu123Leu), gnomAD 7-151471405-C-T, CADD 10.90
Public RHEB analysis runs
- RHEB analysis run — RHEB (293 variants) — completed 2026-08-19